Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Two Apixaban 5 mg Tablet Formulations in Healthy Thai Subjects (Fasting)
TCTR20240811001Phase 1Completed
- Sponsor
- SciGen Ltd
- Start
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised trial of apixaban in venous thromboembolism (VTE), Atrial fibrillation (AFib), deep vein thrombosis (DVT) and 1 more (2 arms), sponsored by SciGen Ltd. Primary endpoint: Primary pharmacokinetic bioequivalence parameters. Started Jan 2025; status: completed.
02
Drugs
apixaban
03
Conditions
venous thromboembolism (VTE)Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on TCTR20240811001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240811001.